The Food and Drug Administration (FDA) is warning healthcare professionals and patients that Ibrance (palbociclib; Pfizer), Kisqali (ribociclib; Novartis), and Verzenio (abemaciclib; Lilly) may cause rare but severe inflammation of the lungs. These agents, which belong to a class of drugs known as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors, are used in combination with hormone therapies for the treatment of hormone-receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer

Cases of interstitial lung disease (ILD) and pneumonitis were identified in clinical trials and postmarket safety databases. Across these trials, 1 to 3% of patients had ILD/pneumonitis of any grade and <1% had fatal outcomes; in some cases, patients had no risk factors for lung disease, while others had at least 1 risk factor. “The overall benefit of CDK 4/6 inhibitors is still greater than the risks when used as prescribed,” the FDA stated in a press release.

Based on these findings, the Agency has approved new warnings regarding the risk of ILD/pneumonitis to the prescribing information and Patient Package Insert for the previously mentioned medications and the entire class of CDK 4/6 inhibitors.

Healthcare professionals are being advised to monitor patients regularly for pulmonary symptoms indicative of ILD and/or pneumonitis, including hypoxia, cough, dyspnea, and interstitial infiltrates on radiologic exams. Treatment should be interrupted immediately in patients with new or worsening respiratory symptoms, and permanently discontinued if severe ILD and/or pneumonitis occurs.

Clinicians and patients can report adverse events associated with these products to the FDA’s MedWatch Program.

Related Articles

For more information visit FDA.gov.

This article originally appeared on MPR